Case Report
Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA

https://doi.org/10.1053/j.ajkd.2019.09.011Get rights and content

Thrombotic microangiopathy (TMA) is an emerging complication of oncologic therapy. Cancer-related causes of renal endothelial cell damage include cytotoxic chemotherapies, radiation given for myeloablation, and direct involvement of renal vasculature by tumor cells. Another class of therapeutic agents that has been implicated in TMA is the vascular endothelial growth factor (VEGF) pathway inhibitors, including the anti-VEGF monoclonal antibody bevacizumab and the VEGF receptor tyrosine kinase inhibitor sunitinib. These TMAs have been termed type II cancer drug–induced TMA and are distinguished from those associated with some cytotoxic chemotherapies (ie, type I) in that they are not dose dependent and patients are more likely to demonstrate some recovery of kidney function. Determination of the cause of TMA in oncologic patients often presents a significant challenge because patients frequently receive multiple chemotherapeutic agents simultaneously and clinicopathologic features often demonstrate substantial overlap, regardless of cause. We present a case of TMA with predominantly chronic features in a 70-year-old patient being treated for adenoid cystic carcinoma of the breast with a single agent, a short interfering RNA targeted against Myc (DCR-MYC).

Index Words

Thrombotic microangiopathy (TMA)
chemotherapy
adverse drug event
anti-cancer agent
short interfering RNA (siRNA)
investigational drug
experimental treatment
renal function
kidney biopsy
onconephrology
oncotherapy
case report

Cited by (0)

Complete author and article information provided before references.

View Abstract